ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1001

Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop-1

Satoshi Yamasaki and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic drugs, cytokines, Osteoblasts, synovial cells, synovial fluid and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint: Cartilage, Synovium and Osteoarthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: There is evidence of osteoclast activation in the inflamed joints of patients with rheumatoid arthritis (RA). Studies that focus on osteoblasts are not sufficient to illustrate the cell functioning in an RA joint. Osteoblast differentiation is regulated by complex environmental stimuli. Among them, Wnt family proteins are thought to promote osteoblast differentiation via stabilization of ß-catenin and activation of TCF transcription. It is now known that the Wnt pathway is blocked with several soluble proteins such as Dockcop-1 (DKK-1) or Sclerostin (SOST). Fibroblast-like synoviocyte (FLS) is a unique articular resident cell and is a therapeutic target for RA, because the cell is believed to play a role in the joint destruction observed in this disease. In this study, we aimed to determine if FLS has an inhibitory effect on Wnt signaling.

Methods: FLS derived from RA patients (Articular Engineering, USA) was cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum. Supernatants were collected from the FLS culture for 24 hours, with or without TNF-α (100 ng/ml, Millipore). The supernatants were added to U2OS culture after the transfection of TCF reporter plasmid, which contains Wnt/ß-catenin responsive consensus sequence (Millipore), by using lipofectamine 2000 to monitor the activity of Wnt3a responsive promoter. Wnt3a (R&D) or lithium chloride (LiCl) was used to activate the Wnt signaling pathway. Anti DKK-1 antibodies were used to neutralize DKK-1 in uupernatants from the FLS. The DKK-1 productions from FLS were measured by ELISA after treatment with TNF-α (100 ng/mL), IL-6 (100 ng/mL) with soluble IL-6 receptor (100 ng/mL), or IL-17A (100 ng/mL) for 24 hours.

 Results: Wnt3a (200 ng/mL) or LiCl (50 mM) clearly increased the luciferase activity, which was effectively suppressed by the addition of supernatants from the FLS culture. The supernatant from FLS treated with TNF-α exhibited a greater inhibitory effect on luciferase activity induced by Wnt3a or LiCl. The inhibitory effects were blocked by anti DKK-1 neutralizing antibodies. DKK-1 was detectable in the FLS culture medium by ELISA, and the concentrations of DKK-1 were higher in the FLS culture medium supplemented with TNF-α, but not with IL-6 or IL-17, compared to the control.

Conclusion: Our data suggests that FLS inhibits osteogenesis by inhibiting osteoblast differentiation, which is achieved by inhibition of the Wnt signaling pathway. DKK-1, an antagonist for Wnt signaling, is one of the soluble factors that might contribute to the inhibition of the Wnt signaling pathway by FLS. The inflammatory milieu may enhance the Wnt signal inhibition by FLS because TNF-α facilitates the secretion of DKK-1 from FLS. Detailed research is required for the clinical application of DKK-1 blockade in promoting bone regeneration in an inflamed joint of a patient with RA.


Disclosure:

S. Yamasaki,
None;

E. Sugiyama,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fibroblast-like-synoviocytes-inhibit-wnt-signaling-pathway-by-secreting-dockcop-1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology